Marshall Wace, LLP Nurix Therapeutics, Inc. Transaction History

Marshall Wace, LLP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$7.86 - $10.08 $1 Million - $1.29 Million	127,509 New	127,509 $1 Million
Q1 2023 May 15, 2023	BUY	$8.56 - $13.26 $184,014 - $285,050	21,497 New	21,497 $190,000
Q1 2022 May 16, 2022	SELL	$12.94 - $29.65 $119,073 - $272,839	-9,202 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$26.43 - $34.5 $243,208 - $317,469	9,202 New	9,202 $267,000

181

68.1M

78K

53.8K

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $923M
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.